Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 702

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

Open access
Kastritis, Efstathios, Palladini, Giovanni, Minnema, Monique C., Wechalekar, Ashutosh D., Jaccard, Arnaud, Lee, Hans C., Sanchorawala, Vaishali, Gibbs, Simon, Mollee, Peter, Venner, Christopher P., Lu, Jin, Schönland, Stefan, Gatt, Moshe E., Suzuki, Kenshi, Kim, Kihyun, Cibeira, M. Teresa, Beksac, Meral, Libby, Edward, Valent, Jason, Hungria, Vania, Wong, Sandy W., Rosenzweig, Michael, Bumma, Naresh, Huart, Antoine, Dimopoulos, Meletios A., Bhutani, Divaya, Waxman, Adam J., Goodman, Stacey A., Zonder, Jeffrey A., Lam, Selay, Song, Kevin, Hansen, Timon, Manier, Salomon, Roeloffzen, Wilfried, Jamroziak, Krzysztof, Kwok, Fiona, Shimazaki, Chihiro, Kim, Jin-Seok, Crusoe, Edvan, Ahmadi, Tahamtan, Tran, NamPhuong, Qin, Xiang, Vasey, Sandra Y., Tromp, Brenda, Schecter, Jordan M., Weiss, Brendan M., Zhuang, Sen H., Vermeulen, Jessica, Merlini, Giampaolo, Comenzo, Raymond L.·2021·New England Journal of Medicine

Abstract

BACKGROUND: Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by deposition of amyloid fibrils of light chains produced by clonal CD38+ plasma cells. Daratumumab, a human CD38-targeting antibody, may improve outcomes for this disease. METHODS: We randomly assigned patients with newly diagnosed AL amyloidosis to receive six cycles of bortezomib, cyclophosphamide, and dexamethasone either alone (control group) or with subcutaneous daratumumab followed by single-agent daratumumab every 4 weeks for up to 24 cycles (daratumumab group). The primary end point was a hematologic complete response. RESULTS: A total of 388 patients underwent randomization. The median follow-up was 11.4 months. The percentage of patients who had a hematologic complete response was significantly higher in the daratumumab group than in the control group (53.3% vs. 18.1%) (relative risk ratio, 2.9; 95% confidence interval [CI], 2.1 to 4.1; P<0.001). Survival free from major organ deterioration or hematologic progression favored the daratumumab group (hazard ratio for major organ deterioration, hematologic progression, or death, 0.58; 95% CI, 0.36 to 0.93; P = 0.02). At 6 months, more cardiac and renal responses occurred in the daratumumab group than in the control group (41.5% vs. 22.2% and 53.0% vs. 23.9%, respectively). The four most common grade 3 or 4 adverse events were lymphopenia (13.0% in the daratumumab group and 10.1% in the control group), pneumonia (7.8% and 4.3%, respectively), cardiac failure (6.2% and 4.8%), and diarrhea (5.7% and 3.7%). Systemic administration-related reactions to daratumumab occurred in 7.3% of the patients. A total of 56 patients died (27 in the daratumumab group and 29 in the control group), most due to amyloidosis-related cardiomyopathy. CONCLUSIONS: Among patients with newly diagnosed AL amyloidosis, the addition of daratumumab to bortezomib, cyclophosphamide, and dexamethasone was associated with higher frequencies of hematologic complete response and survival free from major organ deterioration or hematologic progression. (Funded by Janssen Research and Development; ANDROMEDA ClinicalTrials.gov number, NCT03201965.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2028631

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 702

Metadata

Authors
Kastritis, E., Palladini, G., Minnema, M. C., Wechalekar, A. D., Jaccard, A., Lee, H. C., Sanchorawala, V., Gibbs, S., Mollee, P., Venner, C. P., Lu, J., Schönland, S., Gatt, M. E., Suzuki, K., Kim, K., Cibeira, M. T., Beksac, M., Libby, E., Valent, J., Hungria, V., Wong, S. W., Rosenzweig, M., Bumma, N., Huart, A., Dimopoulos, M. A., Bhutani, D., Waxman, A. J., Goodman, S. A., Zonder, J. A., Lam, S., Song, K., Hansen, T., Manier, S., Roeloffzen, W., Jamroziak, K., Kwok, F., Shimazaki, C., Kim, J.-S., Crusoe, E., Ahmadi, T., Tran, N., Qin, X., Vasey, S. Y., Tromp, B., Schecter, J. M., Weiss, B. M., Zhuang, S. H., Vermeulen, J., Merlini, G., & Comenzo, R. L.
Venue
New England Journal of Medicine
Published
2021-07
Volume
385
Issue
1
Pages
46-58
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W3174070807
Cited by
702
References
28
FWCI
28.65
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. https://app.cochat.ai/papers/10.1056/nejmoa2028631
The paper
Kastritis, E., Palladini, G., Minnema, M. C., Wechalekar, A. D., Jaccard, A., Lee, H. C., Sanchorawala, V., Gibbs, S., Mollee, P., Venner, C. P., Lu, J., Schönland, S., Gatt, M. E., Suzuki, K., Kim, K., Cibeira, M. T., Beksac, M., Libby, E., Valent, J., . . . Comenzo, R. L. (2021). Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2028631

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.